Intelligent Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry
Intelligent Bio Solutions (INBS) has secured its sixth U.S. patent (No. 12259385) for its Intelligent Fingerprinting Drug Screening Cartridge technology. The patent specifically protects the proprietary lateral flow test strip inside the screening cartridge, ensuring protection for all current and future screening products under U.S. intellectual property law.
The company's innovative technology uses fingerprint sweat analysis to detect common drugs of abuse, offering a non-invasive solution for safety-sensitive industries. This development strengthens INBS's competitive position as it prepares to enter the multi-billion dollar U.S. market in 2025.
Following its FDA 510(k) submission in December 2024, INBS is positioning itself to capitalize on the growing global drug screening market. The patent adds to the company's existing IP portfolio, which includes patents for their Sample Collection Cartridge, cartridge housing, and buffer clip design.
Intelligent Bio Solutions (INBS) ha ottenuto il suo sesto brevetto negli Stati Uniti (n. 12259385) per la sua tecnologia di cartuccia per screening dei farmaci con impronta digitale. Il brevetto protegge specificamente il test a flusso laterale proprietario all'interno della cartuccia di screening, garantendo protezione per tutti i prodotti di screening attuali e futuri secondo la legge sulla proprietà intellettuale degli Stati Uniti.
La tecnologia innovativa dell'azienda utilizza l'analisi del sudore delle impronte digitali per rilevare i comuni farmaci d'abuso, offrendo una soluzione non invasiva per le industrie sensibili alla sicurezza. Questo sviluppo rafforza la posizione competitiva di INBS mentre si prepara ad entrare nel mercato statunitense da miliardi di dollari nel 2025.
Dopo la sua presentazione FDA 510(k) nel dicembre 2024, INBS si sta posizionando per capitalizzare sul crescente mercato globale dello screening dei farmaci. Il brevetto si aggiunge al portafoglio di proprietà intellettuale esistente dell'azienda, che include brevetti per la loro cartuccia di raccolta campioni, l'alloggiamento della cartuccia e il design della clip di buffer.
Intelligent Bio Solutions (INBS) ha asegurado su sexta patente en EE. UU. (No. 12259385) para su tecnología de cartucho de detección de drogas con huellas dactilares. La patente protege específicamente la tira de prueba de flujo lateral propietaria dentro del cartucho de detección, asegurando protección para todos los productos de detección actuales y futuros bajo la ley de propiedad intelectual de EE. UU.
La innovadora tecnología de la empresa utiliza análisis de sudor de huellas dactilares para detectar drogas comunes de abuso, ofreciendo una solución no invasiva para industrias sensibles a la seguridad. Este desarrollo fortalece la posición competitiva de INBS mientras se prepara para ingresar al mercado estadounidense de miles de millones de dólares en 2025.
Tras su presentación a la FDA 510(k) en diciembre de 2024, INBS se está posicionando para capitalizar el creciente mercado global de detección de drogas. La patente se suma al portafolio de propiedad intelectual existente de la empresa, que incluye patentes para su cartucho de recolección de muestras, el alojamiento del cartucho y el diseño de la clip de buffer.
인텔리전트 바이오 솔루션즈 (INBS)는 지문 약물 검사 카트리지 기술에 대한 미국 특허 제6호 (No. 12259385)를 확보했습니다. 이 특허는 검사 카트리지 내부의 독점적인 측면 흐름 테스트 스트립을 구체적으로 보호하여, 미국 지적 재산권 법에 따라 현재 및 미래의 모든 검사 제품을 보호합니다.
회사의 혁신적인 기술은 지문 땀 분석을 사용하여 일반적인 약물 남용을 감지하며, 안전이 중요한 산업을 위한 비침습적인 솔루션을 제공합니다. 이 개발은 INBS가 2025년에 수십억 달러 규모의 미국 시장에 진입할 준비를 하면서 경쟁력을 강화합니다.
2024년 12월 FDA 510(k) 제출 이후, INBS는 성장하는 글로벌 약물 검사 시장에서 기회를 포착하기 위해 포지셔닝하고 있습니다. 이 특허는 샘플 수집 카트리지, 카트리지 하우징 및 완충 클립 디자인에 대한 기존의 IP 포트폴리오에 추가됩니다.
Intelligent Bio Solutions (INBS) a obtenu son sixième brevet américain (n° 12259385) pour sa technologie de cartouche de dépistage des drogues par empreinte digitale. Le brevet protège spécifiquement la bande de test à flux latéral propriétaire à l'intérieur de la cartouche de dépistage, garantissant une protection pour tous les produits de dépistage actuels et futurs en vertu de la législation américaine sur la propriété intellectuelle.
La technologie innovante de l'entreprise utilise l'analyse de la sueur des empreintes digitales pour détecter les drogues courantes d'abus, offrant une solution non invasive pour les industries sensibles à la sécurité. Ce développement renforce la position concurrentielle d'INBS alors qu'elle se prépare à entrer sur le marché américain de plusieurs milliards de dollars en 2025.
Suite à sa soumission FDA 510(k) en décembre 2024, INBS se positionne pour tirer parti du marché mondial croissant du dépistage des drogues. Le brevet s'ajoute au portefeuille de propriété intellectuelle existant de l'entreprise, qui comprend des brevets pour leur cartouche de collecte d'échantillons, le boîtier de la cartouche et le design du clip tampon.
Intelligent Bio Solutions (INBS) hat sich sein sechstes US-Patent (Nr. 12259385) für seine Technologie der Fingerabdruck-Drogenscreening-Kartusche gesichert. Das Patent schützt speziell den proprietären Laterale-Fluss-Teststreifen innerhalb der Screening-Kartusche und gewährleistet Schutz für alle aktuellen und zukünftigen Screening-Produkte gemäß dem US-Urheberrecht.
Die innovative Technologie des Unternehmens verwendet Fingerabdruck-Schweißanalyse, um gängige Drogenmissbrauch zu erkennen und bietet eine nicht-invasive Lösung für sicherheitssensible Branchen. Diese Entwicklung stärkt die Wettbewerbsposition von INBS, während das Unternehmen sich darauf vorbereitet, 2025 in den milliardenschweren US-Markt einzutreten.
Nach der Einreichung bei der FDA 510(k) im Dezember 2024 positioniert sich INBS, um vom wachsenden globalen Markt für Drogenscreening zu profitieren. Das Patent erweitert das bestehende IP-Portfolio des Unternehmens, das Patente für ihre Probenahme-Kartusche, das Gehäuse der Kartusche und das Design des Pufferclips umfasst.
- Secured 6th U.S. patent strengthening IP protection for drug screening technology
- FDA 510(k) submission completed in December 2024
- Positioned to enter multi-billion dollar U.S. market in 2025
- Comprehensive patent portfolio covering multiple product components
- No current market presence or revenue from U.S. operations
- FDA approval still pending following 510(k) submission
Insights
This newly secured patent represents a significant strategic milestone for Intelligent Bio Solutions' intellectual property portfolio. As their sixth U.S. patent, it specifically protects the proprietary lateral flow test strip - a fundamental component of their fingerprint-based drug screening technology. The timing is particularly advantageous, coming just before their planned 2025 market entry.
In the mature lateral flow device patent landscape, securing broad protection demonstrates both the novelty of their approach and their comprehensive IP strategy. This patent doesn't exist in isolation but complements INBS's existing patents covering their Sample Collection Cartridge, cartridge housing, and buffer clip design - creating multiple layers of protection around their core technology.
This patent strengthens INBS's competitive moat by establishing significant barriers to entry for potential competitors in the fingerprint sweat-based drug testing space. For a small-cap company (
The December 2024 FDA 510(k) submission, now backed by this patent approval, positions INBS more securely for their commercialization phase, assuming regulatory clearance. This comprehensive approach to IP protection before market entry follows best practices for medical technology companies looking to maximize their competitive positioning.
INBS's fingerprint sweat analysis technology represents a potentially disruptive approach in the drug screening market. Their non-invasive method offers clear advantages over traditional blood, urine, or saliva testing by being less intrusive and potentially faster, addressing key pain points for employers in safety-sensitive industries.
The technology's unique value proposition centers on streamlining drug testing processes while supporting employee dignity - an increasingly important consideration for workplace testing programs. By detecting common drugs of abuse through fingerprint sweat, the system potentially offers comparable efficacy to conventional methods while eliminating many of their drawbacks.
The December 2024 FDA 510(k) submission signals they're in the final regulatory stage before commercialization. This pathway suggests they're positioning their device as substantially equivalent to legally marketed predicate devices, typically a faster route to market than de novo classification.
For organizations needing regular drug screening, INBS's technology could potentially reduce costs associated with traditional testing methods that require specialized collection facilities, trained personnel, and chain-of-custody protocols. Their focus on safety-sensitive industries indicates a targeted B2B strategy aimed at sectors with mandatory testing requirements and high compliance standards.
With the global drug screening market expanding rapidly due to increasing substance abuse concerns and regulatory requirements across multiple industries, INBS appears well-positioned with both their technology approach and now-strengthened IP protection to capture share in this growing market.
Company’s 6th U.S. patent adds to comprehensive IP portfolio protecting its unique drug screening technology
Patent protection strengthens Company’s competitive position as it prepares for planned entry into multi-billion dollar U.S. market in 2025
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that the Company has been granted a patent in the United States (U.S.) relating to its Intelligent Fingerprinting Drug Screening Cartridge. This is the Company’s sixth active patent to be granted in the U.S., strengthening the protection of its unique and proprietary drug screening technology.
U.S. Patent No: 12259385, relates to the proprietary lateral flow test strip inside the Company’s Drug Screening Cartridge and ensures that all current and future screening cartridge products developed by INBS are protected under U.S. intellectual property law. The patent is fundamental to the Company’s testing system, which uses lateral flow technology to detect drugs in fingerprint sweat. This latest patent enhances the Company’s U.S. intellectual property portfolio, which also includes patents covering INBS’ Sample Collection Cartridge, cartridge housing and buffer clip design.
“The intellectual property landscape for lateral flow devices in the U.S. is mature, making the grant of this patent a strong validation of our innovative technology,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. “The U.S. is a key market for us, and securing broad intellectual property protection strengthens our competitive position as we plan for entry into this multi-billion dollar market in 2025.”
The Company's Intelligent Fingerprinting Drug Testing Solution uses fingerprint sweat analysis to detect common drugs of abuse, an area of growing demand across multiple industries who want to ensure their employees are safe to work. The unique, non-invasive solution addresses the challenges faced by safety-sensitive industries, streamlines drug testing processes, and provides an alternative method that supports employee well-being and compliance. With recent FDA 510(k) submission in December 2024 and plans to enter the U.S. market in 2025, INBS is well-positioned to leverage the rapidly expanding global drug screening market.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
For more information, visit: http://www.ibs.inc
Forward-Looking Statements:
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact:
Intelligent Bio Solutions Inc.
info@ibs.inc
LinkedIn | Twitter
Investor & Media Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
PH: (212) 896-1254
INBS@kcsa.com
FAQ
When will Intelligent Bio Solutions (INBS) enter the U.S. drug screening market?
How many U.S. patents does INBS now hold for its drug screening technology?
What is unique about INBS's drug screening technology?
What components are protected by INBS's patent portfolio?
